期刊文献+

采用PCR-测序法对北京地区325例妇女宫颈脱落细胞样品中人乳头瘤病毒进行检测和基因分型 被引量:3

PCR-based sequencing for detection and genotyping of human papillomavirus in 325 cervical cell specimens from Beijing area
原文传递
导出
摘要 为了探讨PCR-测序法在宫颈脱落细胞样品中人乳头瘤病毒(Human papillomavirus,HPV)临床检测中的应用价值,采用HPV通用引物PGMY09/11针对HPV L1区基因序列进行PCR扩增,并通过DNA测序法对HPV进行基因分型。对于混合感染样品,利用HPV型别特异性引物PCR的方法进行基因分型。325例临床样品中,228例为HPV阳性,其中66例为混合感染。共发现27种不同的HPV型别,其中HPV 16比例最多,其次是HPV 58和52。高危型HPV检出率随病变程度加重显著性增加(P〈0.05),但混合感染的比例呈下降趋势(P〈0.05)。在21~30岁年龄组中,HPV感染率最高。PCR-测序法与HC2对高危型HPV检测的符合度较好(kappa=0.675)。PCR-测序法可有效地对宫颈脱落细胞样品进行HPV检测和基因分型,对大规模的HPV筛查具有潜在的应用价值。 To evaluate PCR-sequencing for clinical detection of human papillomavirus(HPV) genotypes in cervical cell specimens,we applied PCR-sequencing to HPV detection and genotyping by general primer PGMY09/11,which targets the HPV most conserved L1 gene.Samples with multiple infections were subjected to HPV type-specific PCR.Among the 325 cervical samples,228 were HPV positive,of which 66 showed multiple infections.In all,27 different HPV genotypes were identified,with HPV 16 being the most prevalent,followed by HPV 58 and 52.The prevalence of high-risk HPV infection increased with the severity of cervical lesions(P0.05),whereas the proportion of multiple infections declined significantly from LSIL to SCC(P0.05).Both rates of overall and high-risk HPV infection were the highest in 21-30 age groups.There was substantial agreement between the HC2 and PCR-sequencing assay for detection of high-risk HPV(kappa=0.675).PCR-sequencing was effective in HPV detection and genotyping,and it could be potentially applied to large scale HPV screening.
出处 《生物工程学报》 CAS CSCD 北大核心 2011年第10期1482-1489,共8页 Chinese Journal of Biotechnology
基金 北京市科技计划(No.D09050703570906) 传染病重大专项(No.2009ZX10601) 中国科学院知识创新工程项目资助~~
关键词 人乳头瘤病毒 宫颈病变 聚合酶链式反应 DNA测序 基因分型 human papillomavirus cervical lesions PCR DNA sequencing genotyping
  • 相关文献

参考文献24

  • 1Jemal DA, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90.
  • 2Yang L, Parkin DM, Li L, et al. Time trends in cancer mortality in China: 1987-1999. Int J Cancer, 2003, 106(5): 771-783.
  • 3Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer world-wide. J Pathol, 1999, 189(1): 12-19.
  • 4Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 2002, 55(4): 244-265.
  • 5Munoz N, Bosch FX, de Sanjos6 S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 2003, 348(6): 518-527.
  • 6Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update, lnt J Cancer, 2007, 121(3): 621-632.
  • 7Salmeron J, Lazcano-Ponce E, Lorincz A, et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control, 2003, 14(6): 505-512.
  • 8Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA, 2000,283(1): 87-93.
  • 9Villa LL, Denny L. Methods for detection of HPV infection and its clinical utility. Int J Gynecol Obstet, 2006,94(S1):S71-S80.
  • 10Coutlee F, Rouleau D, Petignat P, et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol, 2006, 44(6): 1998-2006.

同被引文献30

  • 1Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1).. 9-29.
  • 2Li J, Kang LN, Qiao YL. Review of the cervical cancer disease burden in China's Mainland[J]. Asian Pac J Cancer Prey, 2011, 12 (5).. 1149-53.
  • 3Shi JF, Canfell K, Lew JB, et al. The burden of cervical cancer in China: synthesis of the evidenee[J]. Int J Cancer, 2012, 130 (8) : 641-52.
  • 4Schiffman M, Castle PE, Jeronimo J, et al. Human papilloma virus and cervical cancer[J]. Lancet, 2007, 370(9590): 890-907.
  • 5Burd EM. Human papillomavirus and cervical cancer[J]. Clin Microbiol Rev, 2003, 16(1): 1-17.
  • 6Bosch FX, de Sanjose S. Human papillomavirus in cervical canc- er[J]. CurrOncolRep, 2002, 4(2): 175-83.
  • 7Cutts FT, Franceschi S, Goldie S, et al. Human papillomavirus and HPV vaccines: a review[J]. Bull World Health Organ, 2007, 85(9): 719-26.
  • 8Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classi- fication of human papillomavirus types associated with cervical cancer[J]. NEnglJ Med, 2003, 348(6): 518-27.
  • 9Abreu AL, Souza RP, Gimenes F, et al. A review of methods for detect human Papillomavirus infection[J]. Virol J, 2012, 9: 262.
  • 10de Sanjose S, Quint WG, Alemany L, et al. Human papilloma- virus genotype attribution in invasive cervical cancer: a retrospec- tive cross-sectional worldwide study[J]. Lancet Oncol, 2010, 11 (11): 1048-56.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部